News
An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and ...
UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback